BioNumerik Pharmaceuticals, Inc. Files for Initial Public Offering

San Antonio, TX, June 9 -- BioNumerik Pharmaceuticals, Inc. announced today that it has filed a registration statement for the initial public offering of shares of its common stock.

The underwriters of the offering will be UBS Investment Bank, acting as lead book-running manager, Needham & Company, Inc., Leerink Swann & Company and Punk, Ziegel & Company, acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

A copy of the preliminary prospectus relating to the offering may be obtained when available from UBS Investment Bank's prospectus department at 299 Park Avenue, New York, NY 10171.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About BioNumerik
BioNumerik, headquartered in San Antonio, TX, is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of patients with cancer. BioNumerik has two drug candidates in late-stage clinical development -- Tavocept™ and BNP1350.

For more information contact:
Steve Riebel, Chief Financial Officer
BioNumerik Pharmaceuticals, Inc.
210.614.1701, ext. 221
email: contact@bnpi.com